Potently neutralizing and protective human antibodies against SARS-CoV-2
Natasha M. Kafai(Washington University in St. Louis), Nicole L. Kallewaard(AstraZeneca (United States)), Rachel E. Sutton(Vanderbilt University Medical Center), Ralph S. Baric(University of North Carolina at Chapel Hill), Swathi Shrihari(Washington University in St. Louis), Shamus P. Keeler(Washington University in St. Louis), Jens Meiler(Leipzig University of Applied Sciences), Robert J. Carnahan, Pavlo Gilchuk(AstraZeneca (Japan)), Larissa B. Thackray(Washington University in St. Louis), Michael J. Holtzman(Washington University in St. Louis), James Brett Case(Washington University in St. Louis), Benjamin K. Mueller(Vanderbilt University), Lisa E. Gralinski(University of North Carolina at Chapel Hill), Lauren E. Williamson(Vanderbilt University Medical Center), Julie F. Fox, James E. Crowe(Vanderbilt University Medical Center), Rachel S. Nargi(Vanderbilt University Medical Center), Kuishu Ren(AstraZeneca (United States)), Dan H. Barouch(Beth Israel Deaconess Medical Center), Naveenchandra Suryadevara(Vanderbilt University), Rita E. Chen(Washington University in St. Louis), Noe B. Mercado(Beth Israel Deaconess Medical Center), Andrew Trivette, Yueh–Ming Loo(Intego (Germany)), Joseph X. Reidy(Vanderbilt University Medical Center), Abishek Chandrashekar(Beth Israel Deaconess Medical Center), Michael Diamond(Washington University in St. Louis), Elaine C. Chen(Vanderbilt University Medical Center), Seth J. Zost(Vanderbilt University Medical Center), Taylor Jones(University of Colorado Boulder), James J. Steinhardt(AstraZeneca (United States)), Elad Binshin, Joseph P. Nkolola(Beth Israel Deaconess Medical Center), Ahmed Hassan, Luke Myers, David R. Martinez(Yale University), Emma S. Winkler(Washington University in St. Louis), Samuel B. Day(Vanderbilt University Medical Center), Alexandra Schäfer, Broc T. McCune(Washington University in St. Louis)
Cited by 0
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k